The financial burden of gastrointestinal (GI) diseases in the United States is among one of the highest at $136 billion/year, which is more than the $113 billion/year spent on heart diseases. There are approximately 700,000 gastrointestinal anastomotic surgeries performed worldwide. An anastomosis is a surgical connections between two tubular organs. An anastomosis may be created following the removal of a section of a tubular organ that includes pathologic entities (e.g., tumors). Current methods for creating a GI anastomosis include surgically connecting the remaining sections of the intestine via suturing and/or stapling via laparoscopy or laparotomy. Creating a GI anastomosis using such current methods, however, can be expensive, time consuming, invasive, and result in a high rate of complications.
A major complication that may occur following gastrointestinal anastomotic procedure is leaking of GI content from the anastomosis. Common complications resulting from these leaks include surgical site infection, intraabdominal abscesses, ulcers, gastrointestinal stricture, pneumonia, and septic shock. Leaking of GI content from an anastomosis occurs in about 6% to 30% of cases. Whether an anastomosis leaks is believed to depend, in part, on patient risk factors as well as anastomosis type. In up to 60% of cases, a leaking GI anastomosis requires surgical repair. Complications arising from a leaking GI anastomosis are often especially detrimental due to the bacterial content in the fluids flowing through the GI tract.
The following presents a simplified summary of some embodiments of the invention to provide a basic understanding of the invention. This summary is not an extensive overview of the invention. It is not intended to identify key/critical elements of the invention or to delineate the scope of the invention. Its sole purpose is to present some embodiments of the invention in a simplified form as a prelude to the more detailed description that is presented later.
Bioresorbable tubular organ stent assemblies for creating an anastomosis that connects sections of a tubular organ (e.g., following removal of a section of the tubular organ), and related methods, employ a stent configured to maintain contact between the sections of the tubular organ to promote fusing of the sections via healing. In many embodiments, the tubular stent assembly is configured to isolate the interfaced portions of the sections of the tubular organ from the contents of the tubular organ to inhibit leakage from the anastomosis and better promote fusing of the sections via healing. While the bioresorbable tubular organ stent assemblies and related methods for creating an anastomosis can be adapted for use in creating many different types of an anastomosis (e.g., end-to-end, side-to-side, end-to-side, arterioarterial, venovenous, arteriovenous, circulatory, ductal, stomach, intestinal, etc.), they may be especially beneficial for creating a GI anastomosis due to reduced rates of leakage of GI tract contents and associated reduction in related complications. The bioresorbable tubular organ stent assemblies and related methods for creating an anastomosis may be adapted for use in connecting any suitable tubular structure in a patient (e.g., human, non-human) such as the GI tract (intestines, biliary ducts, etc.), uterine tract (e.g., fallopian tube), urinary tract (ureter), and cardiovascular arteries and veins.
Thus, in many embodiments, a bioresorbable tubular organ stent assembly includes a bioresorbable stent and one or more bioresorbable retention devices. The stent is configured for retaining a first section of a tubular organ in contact with a second section of the tubular organ to accommodate joining of the first section and the second section. A first end portion of the stent is configured to accommodate insertion into the first section of the tubular organ and inhibit removal from the first section of the tubular organ. A second end portion of the stent is configured to accommodate insertion into the second section of the tubular organ and inhibit removal from the second section of the tubular organ. The stent is bioresorbable. The one or more retention devices are configurable to secure the first section and the second section to the stent. Each of the one or more retention devices is bioresorbable.
The bioresorbable tubular organ stent assembly can be used to connect sections of any suitable tubular organ. For example, in many embodiments, the tubular organ is an intestine. In many embodiments, the stent includes a tubular outer wall that defines a lumen configured for fluidly coupling the first section of the tubular organ and the second section of the tubular organ. The tubular outer wall can be configured to block flow of contents of the tubular organ to interfaced portions of the first section and the second section. In many embodiments, the first end portion of the stent includes one or more first end portion retention features and the second end portion of the stent includes one or more second end portion retention features. The one or more first end portion retention features can be configured to interface with the first section of the tubular organ and shaped to accommodate insertion of the first end portion of the stent into the first section of the tubular organ and inhibit removal of the first end portion of the stent from the first section of the tubular organ. The one or more second end portion retention features can be configured to interface with the second section of the tubular organ and shaped to accommodate insertion of the second end portion of the stent into the second section of the tubular organ and inhibit removal of the second end portion of the stent from the second section of the tubular organ. In some embodiments, the one or more first end portion retention features include first end portion protruding barbs and the one or more second end portion retention features include second end portion protruding barbs.
The bioresorbable tubular organ stent assembly can be configured to be implantable using a minimally invasive surgical procedure. For example, the stent can be an expandable stent configured to be expandable from a collapsed configuration to an expanded configuration. The collapsed configuration can be configured to accommodate insertion of the stent through a surgical port. The expanded configuration can be configured for retaining the first section in contact with the second section. In some embodiments, the expandable stent includes an expandable outer membrane configured to block flow of contents of the tubular organ to interfaced portions of the first section of the tubular organ and the second section of the tubular organ. In some embodiments, the expandable stent includes stent links. Each of the stent links can be pivotally coupled with each of an adjacent two of the stent links via pivot joints configured to accommodate expansion of the expandable stent from the collapsed configuration to the expanded configuration and block reconfiguration of the expandable stent from the expanded configuration to the collapsed configuration. Each of one or more of the pivot joints can include a ratchet mechanism configured to accommodate pivoting between a pair of the stent links joined by the pivot j oint in a first rotational direction and block pivoting between the pair of the stent links in a second rotational direction opposite to the first rotational direction. Each of the stent links can form a respective portion of the first end portion of the stent and a respective portion of the second end portion of the stent. Each of stent links can include one or more first end portion retention features and one or more second end portion retention features. The one or more first end portion retention features can be configured to interface with the first section of the tubular organ and shaped to accommodate insertion of the first end portion of the expandable stent into the first section of the tubular organ and inhibit removal of the first end portion of the expandable stent from the first section of the tubular organ. The one or more second end portion retention features can be configured to interface with the second section of the tubular organ and shaped to accommodate insertion of the second end portion of the expandable stent into the second section of the tubular organ and inhibit removal of the second end portion of the expandable stent from the second section of the tubular organ. In some embodiments, the one or more first end portion retention features include first end portion protruding barbs and the one or more second end portion retention features include second end portion protruding barbs.
In many embodiments, the one or more retention devices are operable to clamp the first section and the second section to an exterior surface of the stent. In some embodiments, at least one of the one or more retention devices includes a clamping strap and a ratchet mechanism for adjusting a circumference of the clamping strap. In some embodiments, the one or more retention devices includes at least one of a first clamp and a second clamp. The first clamp can include a first clamping strap and a first ratchet mechanism for adjusting a circumference of the first clamping strap. The second clamp can include a second clamping strap and a second ratchet mechanism for adjusting a circumference of the second clamping strap. In some embodiments, the one or more retention devices include a helical clamping coil configured to clamp the first section of the tubular organ and the second section of the tubular organ to the exterior surface of the stent.
The stent can include any suitable therapeutic compound. For example, in some embodiments, the stent can include an antibacterial coating. In some embodiments, the antibacterial coating includes one or more of cellulose, silver, or a resorbable polymer coating infused with an antibiotic compound.
The stent can include a porous structure. In some embodiments, the porous structure includes interconnected pores.
The stent and the one or more retention devices can be made from one or more suitable bioresorbable materials. For example, the stent and the one or more retentions devices can include one or more of magnesium (Mg), zinc (Zn), iron (Fe), tungsten (W), molybdenum (Mo), polylactic acid (PLA), polyglycolide (PGA), poly(lactic-co-glycolic acid) (PLGA), polyethylene glycol (PEG), polycaprolactone (PCL), poly(glycerol sebacate) (PGS), alginate (all forms), cellulose (all forms), chitosan (all forms), hyaluronic acid (human and animal derived), or collagen (human and animal derived types 1, 2, 3, 4, and 5.
In many embodiments, a method of connecting sections of a tubular organ employs a bioresorbable stent. For example, a method of connecting sections of a tubular organ includes inserting a first end portion of a bioresorbable stent into an open end of a first section of the tubular organ, inserting a second end portion of the bioresorbable stent into an open end of a second section of the tubular organ, and securing the first section and the second section to the bioresorbable stent.
In many embodiments, an intestinal stent assembly include an intestinal stent and one or more retention devices. The intestinal stent is configured for retaining a first section of an intestine in contact with a second section of the intestine to accommodate joining of the first section and the second section via healing. A first end portion of the intestinal stent is configured to accommodate insertion into the first section of the intestine and inhibit removal from the first section of the intestine. A second end portion of the intestinal stent is configured to accommodate insertion into the second section of the intestine and inhibit removal from the second section of the intestine. The intestinal stent is made from one or more bioresorbable materials. The one or more retention devices are configurable to secure the first section of the intestine and the second section of the intestine to the intestinal stent. Each of the one or more retention devices is made from one or more bioresorbable materials.
For a fuller understanding of the nature and advantages of the present invention, reference should be made to the ensuing detailed description and accompanying drawings.
In the following description, various embodiments of the present invention will be described. For purposes of explanation, specific configurations and details are set forth in order to provide a thorough understanding of the embodiments. However, it will also be apparent to one skilled in the art that the present invention may be practiced without the specific details. Furthermore, well-known features may be omitted or simplified in order not to obscure the embodiment being described.
Referring now to the drawings wherein like reference numerals are used to identify identical components in the various views,
Each of the stent links 214 is pivotally coupled with each of an adjacent two of the stent links 214 via pivot joints 222 configured to accommodate expansion of the stent 212 from the collapsed configuration to the expanded configuration and block reconfiguration of the stent 212 from the expanded configuration to the collapsed configuration. In the illustrated embodiment, each of the pivot joints 222 includes a ratchet mechanism configured to accommodate pivoting between a pair of the stent links 214 joined by the pivot joint 222 in a first rotational direction and block pivoting between the pair of the stent links 214 in a second rotational direction opposite to the first rotational direction. Each of the stent links 214 forms a respective portion of the first end portion of the stent and a respective portion of the second end portion of the stent. Each of the stent links 214 includes one or more of the first end portion retention features 26 and one or more of the second end portion retention features 28.
The bioresorbable stents 12, 112, 122, 212 can include one or more therapeutic compounds and configured to elute the one or more therapeutic compounds through direct tissue contact and/or during resorption of the stent. Some non-limiting examples of therapeutic compounds that could be included within the stents 12, 112, 122, 212 are anti-inflammatory compounds, anti-coagulant compounds, antimicrobial compounds, chemotherapy compounds, and/or pain relief compounds.
The bioresorbable stents 12, 112, 122, 212 can be configured to have any suitable length, outer diameter, pre-expanded outer diameter, expanded outer diameter, barb height, and barb area length. Some non-limiting examples of suitable dimensional ranges include stent length in a range from 30 mm to 100 mm, outer diameter in a range of 10 mm to 60 mm, pre-expanded outer diameter in a range of 5 mm to 30 mm, expanded outer diameter in a range from 20 mm to 60 mm, barb height (base to tip) in a range from 0 mm to 1 mm, and bar area length in a range from 100 mm to 220 mm.
Other variations are within the spirit of the present invention. Thus, while the invention is susceptible to various modifications and alternative constructions, certain illustrated embodiments thereof are shown in the drawings and have been described above in detail. It should be understood, however, that there is no intention to limit the invention to the specific form or forms disclosed, but on the contrary, the intention is to cover all modifications, alternative constructions, and equivalents falling within the spirit and scope of the invention, as defined in the appended claims.
The use of the terms “a” and “an” and “the” and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to,”) unless otherwise noted. The term “connected” is to be construed as partly or wholly contained within, attached to, or joined together, even if there is something intervening. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate embodiments of the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.
This application claims the benefit of U.S. Provisional Application No. 63/315,837 filed Mar. 2, 2022, the entire contents of which are hereby incorporated for all purposes in their entirety.
Number | Date | Country | |
---|---|---|---|
63315837 | Mar 2022 | US |